PLRX - Pliant Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
PLRX price evolution
PLRX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $64.72 | $57.68 | $54.95 | $102.53 |
| Short term investments | $431.01 | $465.93 | $500.21 | $474.79 |
| Net receivables | $3 | $2.12 | $1.58 | $3.3 |
| Inventory | ||||
| Total current assets | $505.5 | $534.34 | $565.7 | $588.23 |
| Long term investments | ||||
| Property, plant & equipment | $4.78 | $5.74 | $8.52 | $9.01 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.65 | $6.13 | $9.19 | $9.65 |
| Total investments | $431.01 | $465.93 | $500.21 | $474.79 |
| Total assets | $512.15 | $540.46 | $574.89 | $597.88 |
| Current liabilities | ||||
| Accounts payable | $4.53 | $3.36 | $2.31 | $1.42 |
| Deferred revenue | ||||
| Short long term debt | $1.32 | $2.06 | $2.23 | $2.38 |
| Total current liabilities | $28.52 | $27.39 | $29.52 | $23.15 |
| Long term debt | $10.05 | $10.02 | $12.31 | $12.81 |
| Total noncurrent liabilities | $10.05 | $10.02 | $12.31 | $12.81 |
| Total debt | $11.37 | $12.08 | $14.54 | $15.19 |
| Total liabilities | $38.58 | $37.42 | $41.83 | $35.96 |
| Shareholders' equity | ||||
| Retained earnings | -$499.75 | -$458.64 | -$417.15 | -$375.96 |
| Other shareholder equity | $0.34 | -$1.91 | -$2.24 | -$1.33 |
| Total shareholder equity | $473.58 | $503.05 | $533.07 | $561.92 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $64.72 | $33.69 | $51.66 | $50.88 |
| Short term investments | $431.01 | $297.5 | $148.93 | $226.01 |
| Net receivables | $3 | $2.07 | $2 | $9.28 |
| Inventory | ||||
| Total current assets | $505.5 | $340.31 | $209.44 | $290.75 |
| Long term investments | ||||
| Property, plant & equipment | $4.78 | $9.91 | $10.94 | $4.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.65 | $10.3 | $11.77 | $4.77 |
| Total investments | $431.01 | $297.5 | $148.93 | $226.01 |
| Total assets | $512.15 | $350.61 | $221.22 | $295.53 |
| Current liabilities | ||||
| Accounts payable | $4.53 | $1.58 | $2.97 | $2.02 |
| Deferred revenue | ||||
| Short long term debt | $1.32 | $2.46 | $1.87 | |
| Total current liabilities | $28.52 | $23.91 | $16.83 | $11.6 |
| Long term debt | $10.05 | $9.93 | $5.33 | |
| Total noncurrent liabilities | $10.05 | $13.36 | $5.33 | $0.87 |
| Total debt | $11.37 | $15.81 | $7.19 | |
| Total liabilities | $38.58 | $37.27 | $22.16 | $12.46 |
| Shareholders' equity | ||||
| Retained earnings | -$499.75 | -$338.41 | -$215.09 | -$117.83 |
| Other shareholder equity | $0.34 | -$1.96 | -$0.2 | -$0.03 |
| Total shareholder equity | $473.58 | $313.34 | $199.06 | $283.06 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.25 | $1.33 | ||
| Cost of revenue | ||||
| Gross Profit | $0.25 | $1.33 | ||
| Operating activities | ||||
| Research & development | $33.18 | $32.34 | $33 | $29.27 |
| Selling, general & administrative | $13.85 | $15.35 | $14.57 | $14.15 |
| Total operating expenses | $47.04 | $47.69 | $47.58 | $43.43 |
| Operating income | -$47.04 | -$47.69 | -$47.33 | -$42.09 |
| Income from continuing operations | ||||
| EBIT | -$40.79 | -$41.17 | -$40.87 | -$37.24 |
| Income tax expense | ||||
| Interest expense | $0.32 | $0.32 | $0.32 | $0.31 |
| Net income | ||||
| Net income | -$41.11 | -$41.49 | -$41.19 | -$37.55 |
| Income (for common shares) | -$41.11 | -$41.49 | -$41.19 | -$37.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.58 | $9.69 | $7.57 | $41.82 |
| Cost of revenue | ||||
| Gross Profit | $1.58 | $9.69 | $7.57 | $41.82 |
| Operating activities | ||||
| Research & development | $127.8 | $96.94 | $77.55 | $66.19 |
| Selling, general & administrative | $57.93 | $39.95 | $27.56 | $17.27 |
| Total operating expenses | $185.72 | $136.88 | $105.11 | $83.46 |
| Operating income | -$184.15 | -$127.2 | -$97.53 | -$41.65 |
| Income from continuing operations | ||||
| EBIT | -$160.07 | -$122.53 | -$97.26 | -$41.53 |
| Income tax expense | ||||
| Interest expense | $1.27 | $0.79 | ||
| Net income | ||||
| Net income | -$161.34 | -$123.32 | -$97.26 | -$41.53 |
| Income (for common shares) | -$161.34 | -$123.32 | -$97.26 | -$41.53 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$41.11 | -$41.49 | -$41.19 | -$37.55 |
| Operating activities | ||||
| Depreciation | $1.02 | $1.04 | $1.1 | $1.06 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.15 | $10.36 | $13.05 | $11.92 |
| Total cash flows from operations | -$25.1 | -$36.22 | -$24.76 | -$30.28 |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$0.09 | -$0.6 | -$0.16 |
| Investments | $31.98 | $38.35 | -$22.38 | -$174.04 |
| Total cash flows from investing | $31.92 | $38.25 | -$22.98 | -$174.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.23 | $0.77 | $0.33 | $273.91 |
| Net borrowings | ||||
| Total cash flows from financing | $0.22 | $0.7 | $0.16 | $273.33 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.04 | $2.73 | -$47.58 | $68.84 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$161.34 | -$123.32 | -$97.26 | -$41.53 |
| Operating activities | ||||
| Depreciation | $4.23 | $3.68 | $3.2 | $1.31 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $44.48 | $22.6 | $10.44 | $3.9 |
| Total cash flows from operations | -$116.36 | -$94.63 | -$75.44 | -$37.27 |
| Investing activities | ||||
| Capital expenditures | -$0.92 | -$1.76 | -$1.95 | -$1.53 |
| Investments | -$126.09 | -$148.44 | $75.65 | -$209.33 |
| Total cash flows from investing | -$127.01 | -$150.2 | $73.7 | -$210.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $275.25 | $217.56 | $2.98 | $161.19 |
| Net borrowings | $9.85 | |||
| Total cash flows from financing | $274.4 | $226.85 | $2.53 | $213.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $31.03 | -$17.98 | $0.78 | -$34.92 |
News
Fundamentals
| Market cap | $730.44M |
|---|---|
| Enterprise value | $677.09M |
| Shares outstanding | 59.92M |
| Revenue | $1.58M |
|---|---|
| EBITDA | -$155.84M |
| EBIT | -$160.07M |
| Net Income | -$161.34M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -83.69% |
| P/E ratio | -4.53 |
|---|---|
| EV/Sales | 428.54 |
| EV/EBITDA | -4.34 |
| EV/EBIT | -4.23 |
| P/S ratio | 462.30 |
| P/B ratio | 1.54 |
| Book/Share | 7.90 |
| Cash/Share | 1.08 |
| EPS | -$2.69 |
|---|---|
| ROA | -29.00% |
| ROE | -31.15% |
| Debt/Equity | 0.08 |
|---|---|
| Net debt/EBITDA | 0.17 |
| Current ratio | 17.72 |
| Quick ratio | 17.72 |